article thumbnail

Ensight-AI Awarded FDA’s Breakthrough Device Designation for Its ECGVision-TTR Technology for Early Detection of ATTR-Cardiomyopathy

DAIC

Food and Drug Administration’s ( FDA ) Breakthrough Device Designation for their ECGvision-TTR Technology for early detection of ATTR-Cardiomyopathy. Food and Drug Administration’s (FDA) Breakthrough Devices Program , which provides patients with timely access to innovative medical devices.

article thumbnail

Engineered exosomes: a potential therapeutic strategy for septic cardiomyopathy

Frontiers in Cardiovascular Medicine

Septic cardiomyopathy, a life-threatening complication of sepsis, can cause acute heart failure and carry a high mortality risk. These exosomes can both diagnose and treat septic cardiomyopathy, playing a crucial role in its development and progression. Current treatments have limitations.

article thumbnail

Research landscape of genetics in dilated cardiomyopathy: insight from a bibliometric analysis

Frontiers in Cardiovascular Medicine

BackgroundDilated cardiomyopathy (DCM) is a heterogeneous myocardial disorder with diverse genetic or acquired origins. Notable advances have been achieved in discovering and understanding the genetics of DCM.

article thumbnail

Advances of research in diabetic cardiomyopathy: diagnosis and the emerging application of sequencing

Frontiers in Cardiovascular Medicine

Diabetic cardiomyopathy (DCM) is one of the most prevalent and severe complications associated with diabetes mellitus (DM). Thus, it becomes imperative to uncover innovative approaches to facilitate the prompt identification and diagnosis of DCM. The onset of DCM is insidious, with the symptoms being obvious only in the late stage.

article thumbnail

FDA Clears First AI to Aid Heart Failure Detection During Routine Check-ups

DAIC

This leap in early detection marks both a significant medical innovation and a new era in the detection of cardiovascular disease. specificity, underscoring its significant potential to assist in the detection and appropriate management of cardiomyopathy in pregnant women, reducing associated disease burden and risk of death.5

article thumbnail

Gene Therapy in Cardiovascular Disease: Recent Advances and Future Directions in Science: A Science Advisory From the American Heart Association

Circulation

Innovative strategies have emerged to rectify pathogenic variants that cause monogenic disorders such as hypertrophic, dilated, and arrhythmogenic cardiomyopathies and hypercholesterolemia.

article thumbnail

The Texas Heart Institute Collaborates on Multi-institutional DOD Grant to Develop Novel Left Ventricular Assist Device

DAIC

million grant awarded to Georgia Tech by the United States Department of Defense Congressionally Directed Medical Research Programs (CDMRP) as part of the agency’s call for the development of less invasive treatment technologies for cardiovascular conditions associated with cardiomyopathy. Through a new four-year, $7.8